Metraipolis › archive › dc_59f43ef91bbf

Immune-mediated renal injury and cardiometabolic risk in IgA nephropathy: clinical evidence on telitacicept from a scoping review — Europe PMC PMID:41923906

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41923906
DOI: 10.3389/fnut.2026.1790988
License (as archived): solo-consultazione
Archived: 2026-11-04T08:00:07.304Z
SHA-256 of the archived text: a1d5c6e8497699b602dd5050b47041c8c52798bad37397d70beeac430c57efa1
Stable URL of this page: https://metraipolis.com/documento/dc_59f43ef91bbf

How to cite

Immune-mediated renal injury and cardiometabolic risk in IgA nephropathy: clinical evidence on telitacicept from a scoping review — Europe PMC PMID:41923906 — Europe PMC (en), https://europepmc.org/article/MED/41923906 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_59f43ef91bbf (Metraipolis archive dc_59f43ef91bbf, sha256 a1d5c6e8497699b602dd5050b47041c8c52798bad37397d70beeac430c57efa1)

BibTeX

@misc{dc59f43ef91bbf,
  title = {Immune-mediated renal injury and cardiometabolic risk in IgA nephropathy: clinical evidence on telitacicept from a scoping review — Europe PMC PMID:41923906},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41923906},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_59f43ef91bbf; sha256 a1d5c6e8497699b602dd5050b47041c8c52798bad37397d70beeac430c57efa1},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41923906. Agents can read the archived copy with the MCP tool read_document.